# OncoNano Medicine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/onconano-medicine

- Industry: Biotechnology
- Headquarters: Southlake, US
- Website: www.onconanomed.com
- Total disclosed funding: $49M
- Latest round: Series B (Jun 15, 2021)
- Investors on record: 2

## About

OncoNano Medicine, Inc. is a biopharmaceutical company focused on developing innovative therapies for cancer treatment, leveraging advanced technology to enhance drug delivery and efficacy.Founded in 2014, OncoNano Medicine, Inc. operates from its headquarters in Southlake, US, and specializes in developing treatments for cancer. The company has secured funding through multiple rounds, including a Series B round in June 2021, raising USD 49.07 mn, led by Advantech Capital in collaboration with the Cancer Prevention & Research Institute of Texas. The company was co-founded by Baran Sumer and Jinming Gao, and is currently led by CEO Marty Driscoll. The total amount raised by the company to date is USD 49.07 mn, with a current company valuation of USD 129.20 mn.OncoNano Medicine, Inc. focuses on developing cutting-edge therapeutic solutions that enhance drug delivery for cancer treatment. Their primary product offerings are centered around innovative technologies that improve the effectiveness of cancer medications, particularly in targeting and treating tumors. The company’s solutions aim to address significant challenges in cancer therapy through advances in drug formulation and delivery mechanisms, serving a wide range of clients in the healthcare sector.The company's revenue is generated through various channels associated with its therapeutic development programs and partnerships in the biopharmaceutical industry. Clients typically engage in long-term agreements that ensure ongoing collaboration in drug development and testing. These agreements foster stable revenue streams as the company continues to advance its innovative therapies and expand its client base.Following the Series B funding round in June 2021, OncoNano Medicine, Inc. plans to utilize the USD 49.07 mn raised to support Phase 3 clinical trials in both the U.S. and Europe. Additionally, the company aims to accelerate the advancement of its first therapeutic development program. The strategic focus includes potential expansion into new geographic markets, particularly within Europe, by 2023, enhancing their global reach in cancer treatment solutions.

## Funding rounds

- Series B, Jun 15, 2021, $49M — Cancer Prevention & Research Institute of Texas, Advantech Capital

## Investors

- Cancer Prevention & Research Institute of Texas — Series B
- Advantech Capital (https://capitalatlas.ai/funds/advantech-capital) — Series B